VeinWay

VeinWay is focused on developing a novel technology for crossing chronically occluded veins. VeinWay's Traversa delivers the first dedicated device designed for venous recanalization that will improve outcomes and allow physicians to reliably, safely and easily complete endovascular procedures in a timely manner for the effective treatment of CVOs. The Traversa is an enabling technology which will disrupt the market by democratizing physician access to the treatment of CVOs. The innovation has a significantly different approach compared to existing solutions on the market or that are currently in development. All other solutions are either off-label tools that have a high risk of perforation, or standard crossing tools with no specific indication or features for venous recanalization. Physicians use them as workarounds when the procedure fails with standard guidewires. In contrast, Traversa is the first tool designed specifically for crossing CVOs, allowing for an unparalleled level of control that will enable interventional radiologists and vascular surgeons to cross occlusions every time. VeinWay was created as part of the entrepreneur in residence program with the MEDX Xelerator, which supports and helps inventors and entrepreneurs cultivate early-stage ideas addressing complex unmet clinical needs.

VeinWay has raised $7.43M in total funding across 4 rounds. The company is currently at the A stage. Key investors include Consensus Business Group (CBG), Boston Scientific.

VeinWay was founded in 2020 by Jordan Pollack (Co-founder & CEO), Ben Friesem (Co-founder & CTO).

VeinWay operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics. Target customers: Healthcare & Life Sciences, Healthcare, Providers.

VeinWay is based in Ariel Sharon Boulevard 8, Or Yehuda, Israel, Center District.